Grade: Research grade

Factory Location: Hangzhou

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe, Australasia,Asia,Middle East,Africa

Monthly Production Capacity: hundreds of grams

Packaging Information: 500mg,1g, 10g,50g 100g per package with icebag

Delivery Lead Time: In stock or 2-3weeks

Sample Provided: yes

Payment Terms: T/T

Human antimicrobial peptide LL-37 has strong antibacterial and anti-inflammatory activity, broad-spectrum antibacterial effect number, but due to its relatively large molecular weight, and low cell selectivity in the body, coupled with high production costs, it limits LL -37 Application in treatment. Therefore, a new short α-helical antimicrobial peptide derived from LL-37 was developed. This type of antimicrobial peptide with a shorter sequence has better cell selectivity, and compared with LL-37, its anti-inflammatory activity is not significantly lost. LL-37 FK-13 is one of the short α-helix antimicrobial peptides derived from LL-37. It consists of 13 amino acids and has high cell selectivity and anti-inflammatory activity. Studies have shown that LL-37 FK-13 can kill microbial cells by penetrating the cell membrane and destroying the integrity of the membrane.